Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials
Lisa A. Beck(University of Rochester Medicine), A. Gadkari(Regeneron (United States)), Marius Ardeleanu(Regeneron (United States)), Z. Chen(Regeneron (United States)), Laurent Eckert(Sanofi (France)), Stefan Plaum(Sanofi (United States)), Neil M.H. Graham(UK Dementia Research Institute), Gianluca Pirozzi(Sanofi (United States)), Eric L. Simpson(Oregon Health & Science University), Isabelle Guillemin, Jonathan I. Silverberg(George Washington University), M. Ruddy(Regeneron (United States)), Gil Yosipovitch(University of Miami)
Cited by 13
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k